TICKERNERD
Menu
LTRNLTRNHealthcare · Biotechnology

LTRN Stock Forecast: Lantern Pharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.91
−4.61% on the day

The 2 Wall Street analysts covering Lantern Pharma, Inc. hold a median 12-month price target of $18 — +1823.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 7 Oct 2026 — in the lower half.

Market cap
$14.0M
Ticker Nerd rank
45 / 100
Median analyst target
$18
Analysts covering
2
Revenue$0.0
Operating income−$3.5M
Net income−$7.1M
Free cash flow−$2.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
−52.2%
YTD
−70.0%
1Y
−80.0%
From 52W high
−80.3%
From 52W low
+5.8%
$0.86
$4.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LTRN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lantern Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Growth
82
Accruals
80
Issuance
57
Revisions
51
Value
31
Volatility
20
Quality
15
Momentum
11

Size (90): Smaller than most of the companies we track.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LTRN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LTRN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26LTRNHigh $25Median $18Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $18High $25

The green dot is the last close — the median target sits +1823.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Apr 2025Lake StreetInitiatesBuy—
2 Apr 2025Lake StreetInitiatesBuy$25
25 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
10 Aug 2023EF HuttonReiteratesBuy—
26 June 2023EF HuttonMaintainsBuy—
25 May 2023EF HuttonAssumesBuy$11
18 May 2023HC Wainwright & Co.InitiatesNeutral—
21 Mar 2023EF HuttonReiteratesBuy—
15 Feb 2023EF HuttonMaintainsBuy—
1 Nov 2022EF HuttonInitiatesBuy—
11 Mar 2022HC Wainwright & Co.MaintainsBuy—
2 Nov 2021HC Wainwright & Co.MaintainsBuy—
7 Oct 2021HC Wainwright & Co.InitiatesBuy—
28 July 2020Colliers SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTRN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LTRN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Lantern Pharma, Inc. returned −80.0% against +17.4% for the S&P 500, dividends included.

LTRN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26LTRNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LTRN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Lantern Pharma, Inc. (LTRN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
−3.7×

Cheaper than 96% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−400.9%

Higher than 4% of US stocks

Return on assets
−74.3%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lantern Pharma, Inc. (LTRN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lantern Pharma, Inc. has a market value of $14.0M and an enterprise value of $4.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.1M.

  • Shares outstanding: 12.8M.

  • Trailing P/E: −0.6×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lantern Pharma, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

LTRN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LTRNLantern Pharma, Inc.$14.0M
45
INABIN8bio, Inc.$13.7M
50
CTXRCitius Pharmaceuticals, Inc.$13.8M
21
TPSTTempest Therapeutics, Inc.$13.4M
46
CLRBCellectar Biosciences, Inc.$14.3M
27
HINDVyome Holdings, Inc.$14.3M
64
PLURPluri, Inc.$12.8M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lantern Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LTRN news & analysis

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Business Wire · 7 Oct 2026positive

Lantern Pharma received Taiwan regulatory and IRB approvals to open Part 2 of its Phase 2 HARMONIC™ trial of LP-300. The TFDA approved the amended protocol earlier in September, and the lead Taiwan site received IRB approval on September 29, 2026.

Why it matters — The approvals allow the next stage of the company’s LP-300 trial to open at its lead site in Taiwan.

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Business Wire · 30 Sept 2026neutral

Lantern Pharma Inc. announced the closing of a registered direct offering of up to $8 million. The company made the announcement via Business Wire from its Dallas headquarters.

Why it matters — The closing of this registered direct offering provides Lantern Pharma with additional capital, which is relevant to investors tracking the company's funding and financial position.

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

Business Wire · 29 Sept 2026neutral

Lantern Pharma Inc. announced it has entered into a definitive agreement for a registered direct offering of up to $8 million, involving the sale of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share. The clinical-stage, AI-native biopharma company uses artificial intelligence and genomic data to develop precision oncology therapies.

Why it matters — LTRN watchers would track this registered direct offering as it represents a capital-raising event that affects the company's share count and funding position without expressing a view on the merits of the financing.

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript

Seeking Alpha · 23 Sept 2026neutral

Lantern Pharma (LTRN) issued a transcript of a discussion covering its open-medicine AI platform roadmap, business model, and value proposition for therapeutic development. The transcript outlines the company's AI-driven approach to drug development for oncology.

Why it matters — For LTRN watchers, the transcript provides direct insight into the company's AI platform strategy and how it plans to create value in therapeutic development.

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

Business Wire · 23 Sept 2026neutral

Lantern Pharma, Inc. announced it will present on its Agentic AI drug development platform today at 12:30 PM ET. The presentation will cover the drug development market, user needs, development roadmap, platform economics, and benchmarks.

Why it matters — LTRN watchers would care because the presentation provides insight into the company's AI drug development platform strategy, roadmap, and market positioning.

FAQ

Frequently asked questions about LTRN stock

What is the LTRN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lantern Pharma, Inc. have a median 12-month price target of $18, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LTRN stock a buy right now?

Of the 2 analysts covering Lantern Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lantern Pharma, Inc. 45 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LTRN?

As at 7 Oct 2026, Lantern Pharma, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will LTRN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1823.1% from the last close, and Ticker Nerd's factor model ranks Lantern Pharma, Inc. 45 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LTRN stock forecast for 2030?

No analyst covering Lantern Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.

How has LTRN stock performed over the past year?

Lantern Pharma, Inc. returned -80.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lantern Pharma, Inc. do?

Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development.

What is the latest news on LTRN?

The most recent item we track (Business Wire, 7 Oct 2026): "Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC". Lantern Pharma received Taiwan regulatory and IRB approvals to open Part 2 of its Phase 2 HARMONIC™ trial of LP-300. The TFDA approved the amended protocol earlier in September, and the lead Taiwan site received IRB approval on September 29, 2026.

Company

About Lantern Pharma, Inc.

Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development. Lantern Pharma uses artificial intelligence, machine learning, and genomic data through its proprietary RADR platform to identify precision cancer therapies and match them with the patient groups most likely to benefit. Its current portfolio includes multiple lead drug candidates and an antibody-drug conjugate program spanning several cancer indications, including solid tumors, blood cancers, and rare oncology settings. The company’s work centers on accelerating the development of targeted cancer treatments and improving the efficiency of clinical research through data-driven drug design and patient selection. Lantern Pharma Inc. is based in Dallas, Texas, and operates at the intersection of biotechnology, computational biology, and precision medicine.

CEO Mr. Panna Sharma · 16 employees · United States · https://www.lanternpharma.com